Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 21.28 CNY -1.07%
Market Cap: 11.1B CNY
Have any thoughts about
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?
Write Note

Gross Margin
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

94.4%
Current
95%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
94.4%
=
Gross Profit
853.6m
/
Revenue
904.6m

Gross Margin Across Competitors

Country CN
Market Cap 11.3B CNY
Gross Margin
94%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 755.8B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.1B USD
Gross Margin
69%
Country US
Market Cap 251.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.5B USD
Gross Margin
71%
No Stocks Found

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Glance View

Market Cap
11.1B CNY
Industry
Pharmaceuticals

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. emerged on the healthcare scene in China with an unwavering focus on improving allergy treatments. Founded in 1992, the company has carved a niche in the bio-pharmaceutical industry by specializing in the research, development, and manufacturing of allergen-specific immunotherapeutic products. At its heart, Wolwo operates with a clear mission: to diminish the burden of allergic diseases. The company leverages cutting-edge bio-pharmaceutical technologies to produce allergen detection and treatment products, thereby offering innovative solutions to millions affected by allergic conditions. As allergies become more prevalent worldwide, Wolwo's focus on this segment positions it as a critical player in the healthcare market. Wolwo’s business model revolves around the development and commercialization of standardized allergen products. It generates revenue primarily from the sale of its patented therapeutic solutions targeting common allergens such as pollen, dust mites, and pet dander. This involves a deep dive into biotechnology, where their R&D teams continuously innovate to refine product offerings. The company has earned regulatory approvals across various regions, which significantly bolsters its revenue stream and expands its market footprint. Beyond just product sales, Wolwo actively engages in educational programs aimed at raising awareness about allergies, thus creating a well-rounded approach not only in tackling allergic diseases but also in ensuring long-term consumer loyalty and brand trust in a rapidly evolving market.

Intrinsic Value
22.63 CNY
Undervaluation 6%
Intrinsic Value
Price
Z

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
94.4%
=
Gross Profit
853.6m
/
Revenue
904.6m
What is the Gross Margin of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?

Based on Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's most recent financial statements, the company has Gross Margin of 94.4%.